Bayer Loses Yaz Patent in Federal Court of Appeals: Generic Yaz Versions Begin (Stealing) Marketshare
Bayer was recently dealt a setback in a Federal Court of Appeals in Washington. Their patent on Yaz, a contraceptive pill, was deemed to no longer be worthy of patent protection. Bayer’s patent on Yaz expires in June 2014. As a result of this ruling, Actavis Inc. and Novartis AG can sell generic versions of the birth control pill. Though the ruling now gives other pharmaceutical companies the ability to legally compete against Bayer in the drospirenone contraceptive pill market, generic and inexpensive versions of Yaz-like drugs are driving Continue Reading
Contraceptive Nuvaring Linked to Blood Clots and Stroke
Published November 12, 2012 by LawsuitInformation.org Nuvaring is a contraceptive device manufactured by Organon. It was approved by the U.S. Food and Drug Administration (FDA) in 2001. Organon developed and manufactured Nuvaring on the premise of introducing a new form of birth control, one that would supposedly be easier for women to use. However, it soon became apparent after the release of Nuvaring that there were serious issues with the contraceptive device. Questions began to arise as to the verity of Organon’s marketing campaign promoting Nuvaring, especially regarding third-generation Continue Reading
Bayer 2012 Profits Impacted by Yaz and Yasmin Lawsuits
Published August 23, 2012 on LawsuitInformation.org It has been reported that Bayer, the German pharmaceutical giant responsible for the development of Yaz and Yasmin, the health threatening birth control pills of ill repute, has created what is essentially a savings account in the amount of 500 million euros for the purpose of future Yaz and Yasmin lawsuits. In a study conducted by the U.S. Food and Drug Administration (FDA) of Yaz and Yasmin, the FDA uncovered the high risk of blood clot development and a number of other serious Continue Reading
Yaz/Yasmin DVT & Pulmonary Embolism Settlements Progressing
Published July 10, 2012 by LawsuintInformation As a Yaz Pulmonary Embolism, Deep Vein Thrombosis Attorney I have written extensively about the risks inherent in birth control pills containing Drospirenone. According to status report held on June 22, in the U.S. District Court for the Southern District of Illinois, Bayer has reached agreements with about 33 different law firms to resolve at least 1,444 Yaz Deep Vein Thrombosis, Stroke and Pulmonary Embolism claims. According to Bloomberg News, as of late April, Bayer faced 11,900 lawsuits over Yaz and its sister Continue Reading
Controversy Surrounds the FDA’s Decision to Keep Yaz On the Market
Published June 20, 2012 on LawsuitInformation.org The FDA recently mandated that Bayer Pharmaceuticals change the warning labels on two of its most popular birth control pills to reflect recent research relating to blood clots as a result of Yasmin or Yaz. The decision comes in the midst of many ongoing lawsuits against Bayer and generic Yasmin or Yaz manufacturers relating to side effects resulting from Yaz, and has been met with criticism from watchdog groups and other advocacy groups accusing the FDA of not doing enough. FDA addresses concerns Continue Reading
Update June 2012: Yaz & Yasmin Court Information
Published June 21, 2012 on LawsuitInformation.org Yaz Lawsuit Court Info (6/13/12) — Seedol The latest addition to Yaz Lawsuit news is that attorneys are still taking cases for those whose health was severely affected through the use of this birth control. Yaz, Yasmin and other drospirenone-containing birth controls have been linked to devastating blood clots that can cause young victims to be on blood-thinning medication for the remainder of their lives. Many Yaz Lawsuits have been pursued for blood-clot related issues like a stroke, pulmonary embolism or deep vein Continue Reading
Effects of the Mensing Ruling on Yaz & Yasmin Lawsuits
Published June 4, 2012 on LawsuitInformation.org Yaz Lawsuit and The Mensing Ruling The Mensing Ruling refers to a ruling by the Supreme Court in the case of Pliva, Inc., et al. v. Mensing which essentially protected generic manufacturers from lawsuits for failure to warn about any side effects of their products beyond the warnings contained on the warning label of the name Brand product of which they are a “copy”. The ruling does not effect the Yaz Lawsuit or the Yazmin Lawsuit however, it may effect women who took Continue Reading
Bayer Yaz and Yasmin Lawsuit Settlements Climb to $142 Million
Published April 26, 2012 by LawsuitInformation.org Bayer AG (BAYN) said settlements of U.S. lawsuits claiming that its Yasmin line of birth-control pills caused blood clots in women have increased to $142 million. Bayer, based in Leverkusen, Germany, has resolved 651 cases alleging its Yasmin and Yaz contraceptives caused sometimes- fatal clots that can lead to heart attacks and strokes, the company said today in its Stockholders’ Newsletter for the first quarter. The company said it paid $142 million in the settlements, for an average of about $218,000 a case. Continue Reading
Yaz Settlements Reach into Millions
Published May 7, 2012 on LawsuitInformation.org Settlements for plaintiffs who have experienced serious side effects associated with the popular birth control medications Yaz and Yasmin have reached into the millions, after hundreds of plaintiffs received Yaz side effects settlements recently. Yaz drug maker Bayer has agreed to pay out at least $110 million in order to settle 500 lawsuits involving Yaz blood clots. This settlement news comes when the number of Yaz lawsuits that has already been filed has peaked at 11,000, with plaintiffs claiming that Yaz blood clots, Continue Reading
Judge Extends Yaz Lawsuit Deadlines to Allow More Settlements
Published May 7, 2012 on LawsuitInformation.org A judge overseeing the multidistrict litigation (MDL) regarding the oral contraceptive Yaz has cleared the way for more settlement negotiations to continue. Chief Judge David R. Herndon, of the U.S. District Court for the Southern District of Illinois, moved back the deadlines for Yaz lawsuits, allowing for the drug’s maker, Bayer, and attorneys to negotiate settlements for the more than 11,000 remaining lawsuits regarding the blood clot risks associated with the drug. This is the third time the judge has granted a deadline Continue Reading
